Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.
To ascertain the level of acceptance of a prophylactic HIV vaccine trial in high-risk HIV-seronegative heterosexual cohorts of men and women in Mombasa, Kenya, and to assess the anticipated effects of participation on risk behavior.
Standardized questionnaire administered to a convenience sample of commercial sex workers and trucking company employees enrolled in prospective cohort studies.
Ninety-six per cent of respondents believed that HIV was a major problem in Kenya and 86% of men and 94% of women perceived themselves at risk.
One hundred per cent of women and 84% of men expressed interest in participation in an HIV vaccine trial, after explanation of the experimental nature of the vaccine, double-blind placebo-controlled design, prolonged follow-up and potential change in serostatus.
Seventeen per cent of men and 9% of women anticipated an increase in risk behavior as a result of participation.
The majority of individuals in two high-risk cohorts were interested in participating in Phase III efficacy trials of HIV vaccines.
A significant minority anticipated an increase in risk behavior, which emphasizes the need for intensive counseling and education throughout a vaccine trial.
Mots-clés Pascal : SIDA, Virose, Infection, Hétérosexualité, Acceptation, Homme, Essai clinique, Immunoprophylaxie, Vaccin, Facteur risque, Kenya, Afrique, Immunopathologie, Immunodéficit, Prévention
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Heterosexuality, Acceptance, Human, Clinical trial, Immunoprophylaxis, Vaccine, Risk factor, Kenya, Africa, Immunopathology, Immune deficiency, Prevention
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0589210
Code Inist : 002B06D01. Création : 01/03/1996.